|
Summary Information: Axsome Therapeutics Inc. Common Stock NASDAQ:AXSM |
  [email protected] |
Our Main Pages Stocks.TRoach.Net TRoach.Org TRoach.Net |
_Description: Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people facing unsatisfactory treatments for CNS disorders, Axsome accelerates the invention and adoption of life-changing medicines. Axsome's core CNS product candidate portfolio includes five clinical-stage candidates, AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14. AXS-05 is being developed for major depressive disorder (MDD), Alzheimer's disease (AD) agitation, and as a treatment for smoking cessation. AXS-07 is being developed for the acute treatment of migraine. AXS-12 is being developed for the treatment of narcolepsy. AXS-14 is being developed for fibromyalgia. AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14 are investigational drug products not approved by the FDA.
__The following are links to various summary and news pages for __Axsome Therapeutics Inc. Common Stock [ AXSM ]. __Note: Some Links might not have information for the company. |
|